VolitionRx Limited (VNRX), a multinational epigenetics company listed on NYSE American, develops blood-based diagnostic tests to detect and monitor cancers and diseases tied to NETosis — the process in which immune cells called neutrophils release webs of DNA known as NETs (neutrophil extracellular traps). Its platforms include Nu.Q Vet, Nu.Q NETs, Nu.Q Cancer, and Capture-PCR. The stock trades as a micro-cap and has been among the most volatile names in the diagnostics sector.
Three current, attributable price targets were reviewed. Justin Walsh of JonesTrading reiterated a Buy and raised his target to $24 in May 2026, citing the under-recognized Nu.Q platform. Michael Okunewitch of Maxim Group reinstated coverage with a Buy and a $4 target in June 2026. Yi Chen of H.C. Wainwright maintained a Buy with a $1.00 target in April 2026. The arithmetic mean of these three is approximately $9.67, rounded to a central target of $10, with a range of $1.00 to $24.00.
The dispersion is extreme: the highest target is 24 times the lowest. This reflects genuine uncertainty about dilution, reverse-split-adjusted share counts, funding needs, and the timeline to commercial revenue. It is important to note that third-party aggregators publish different averages — some near $13 to $17 — depending on which targets and dates they include. D. Boral Capital, which previously carried a Buy, downgraded the stock to Hold in April 2026 and no longer publishes a target, a notable shift in conviction.
VolitionRx shares recently traded near $0.19, giving the company a market capitalization of roughly $5.8 million. Reaching $10 from $0.19 requires a gain of approximately 5,100% — a very large move by any standard. The path would require not just a technical re-rating but a fundamental transformation: sustained revenue growth, material cost reduction, and evidence that its diagnostics can scale commercially.
Third-quarter 2026 results, reported in November, showed revenue of $1.61 million, up from about $0.63 million a year earlier, while the net loss narrowed to roughly $3.8 million from $5.4 million. For the first nine months of 2026, revenue reached about $3.0 million versus $1.28 million a year prior, but the net loss remained substantial at about $17.8 million. This is a company in the earliest stages of monetizing its technology.
Several verified developments underpin the bullish case. The company's Nu.Q NETs assay was selected as the sole biomarker for France's DETECSEPS program, a roughly €6.3 million (about $7.3 million) government-funded effort to advance early sepsis detection. A landmark clinical validation of Nu.Q NETs was published in Critical Care Medicine, and a rapid point-of-care finger-prick prototype showed strong correlation with the existing lab assay. VolitionRx also announced a collaboration with Sysmex and prepaid its $7.5 million convertible note, reducing equity overhang. Revenue more than doubled year over year, and management has pursued aggressive cost reductions, including further CEO salary cuts.
The obstacles are substantial. Trailing-twelve-month net income is deeply negative — a loss of roughly $26.1 million against revenue of about $2.46 million — and the company carries negative equity with only about $2.79 million in cash. This implies continued equity financings that dilute existing shareholders. The stock trades near its 52-week low and has fallen roughly 97% over the past year. VolitionRx is also operating under a compliance plan accepted by NYSE American in April 2026, meaning a failure to meet continued-listing standards could force a delisting or migration to a less liquid venue. Early-stage diagnostics frequently face regulatory, reimbursement, and adoption hurdles that can stretch timelines far beyond analyst assumptions.
The stock trades near its 52-week low of approximately $0.16, with the $0.16–$0.20 zone representing the nearest area of support. The 52-week range extends up to roughly $9.60, a prior high that now sits far above the market. With a market capitalization in the single-digit millions and a low nominal share price, the structure is dominated by penny-stock dynamics: wide spreads, high volatility, and sensitivity to dilution announcements. No meaningful resistance stands between the current price and the $10 target because the move would require a complete re-rating rather than a breakout through a technical zone.
Analyst price targets generally reflect a research horizon of about 12 months, though firms do not uniformly state one for this name, and the wide target range suggests very different assumptions about timing. Key items to watch include quarterly revenue and cash-burn trends, progress in licensing discussions, Nu.Q Vet commercialization milestones, the France DETECSEPS rollout, any new equity offerings, and whether the company can satisfy its NYSE American listing requirements. Given the company's small cash balance, the cadence and terms of future financings are likely to matter as much as the clinical data.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile micro-cap like VolitionRx, where price moves can be sharp and driven by news and dilution, such tools can help traders discover opportunities, monitor positions, and spot shifting trends more efficiently than manual scanning. Explore the signals to see how automated analysis reads the current tape.
The $10 central target — the mean of three Buy-rated analyst targets ranging from $1.00 to $24.00 — is less a near-term price forecast and more a reflection of the enormous upside embedded in a stock that has lost roughly 97% of its value. Reaching it would require roughly a 5,100% gain, a transformation supported in theory by accelerating revenue and promising sepsis diagnostics, but weighed down by persistent losses, negative equity, minimal cash, dilution risk, and a listing-compliance plan. The extraordinary dispersion among analysts underscores that this is a high-risk, early-stage story. Investors should treat the target as a long-dated, speculative scenario and monitor funding, clinical adoption, and listing status before drawing any conclusion about whether the stock can approach $10.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that VNRX and LAB have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that VNRX and LAB's prices will move in lockstep.
| Ticker / NAME | Correlation To VNRX | 1D Price Change % | ||
|---|---|---|---|---|
| VNRX | 100% | +24.66% | ||
| LAB - VNRX | 27% Poorly correlated | +8.60% | ||
| STRRP - VNRX | 27% Poorly correlated | N/A | ||
| SSII - VNRX | 26% Poorly correlated | +25.76% | ||
| BMRA - VNRX | 26% Poorly correlated | +3.03% | ||
| IMDX - VNRX | 24% Poorly correlated | -7.36% | ||
More | ||||
| Ticker / NAME | Correlation To VNRX | 1D Price Change % |
|---|---|---|
| VNRX | 100% | +24.66% |
| Health Services category (238 stocks) | -4% Poorly correlated | -1.01% |
| Medical/Nursing Services category (138 stocks) | -5% Poorly correlated | -1.10% |